

IRW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Applicant:

Iris PECKER et al

Serial No.: 10/785,116

Filed: February 25, 2004

For: Polynucleotide Encoding A Polypeptide Having
Heparanase Activity And Expression Of Same In
Genetically Modified Cells

Examiner:

§
§
§
§
§
§
§
§
§
§
§

Group Art Unit: 1652

Attorney
Docket: 27674

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Enclosed is a PTO Form 1449 which lists citations which may be material to the patentability and examination of the above identified application. Also enclosed are copies of all other references have been received by the Examiner through corresponding applications. These are submitted in compliance with the duty of disclosure defined in 37 CFR 1.56. The Examiner is requested to make these citations of official record in this application.

Applicant requests that MPEP 609 III A(2)(E) be complied with and the examiner consider information which has been considered by the Office in a parent applications thereof. A listing of the references cited in those applications follows on the attached PTO/SB/08A. Applicant respectfully requests that they be made of record in the instant application.

This application is a continuation of U.S. Patent Application No.09/988,113, filed November 19, 2001, which is a continuation of U.S. Patent Application No. 09/776,874, filed February 06, 2001, which is a continuation of U.S. Patent Application No. 09/258,892, filed March 1, 1999, now abandoned, which is a continuation-in-part of PCT/WO98/17954, filed August 31, 1998, which claims priority from U.S. Patent Application 09/109,386 filed July 2, 1998, now abandoned, which is a continuation-in-part of U.S. Patent Application 08/922,170 filed September 2, 1997, now, U.S. Patent No. 5,968,822.


This Information Disclosure Statement under 37 CFR 1.56 is not to be construed as a representation that a search has been made, that additional matter which is material to the examination of this application does not exist, or that any or more of these citations constitutes prior art.

Respectfully submitted,

Martin D. Moynihan

Martin Moynihan
Registration No. 40,338

Dated: July 19, 2005



PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	10/785,116
Filing Date	February 25, 2004
First Named Inventor	PECKER Iris et al
Art Unit	1652
Examiner Name	
Attorney Docket Number	27674

Sheet

of

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	1	US-5,362,641	08-8-1994	Fuks et al.	
	2	US-5,399,351	03-21-1995	Leshchiner et al	
	3	US-5,550,116	08-27-1996	Lormeau et al.	
	4	US-5,667,501	09-16-1997	Fowler et al.	
	5	US-5,739,115	04-14-1998	Fugedi et al	
	6	US-6,177,545	01-13-2001	Pecker et al.	
	7	US-6,348,344	02-19-2002	Ayal-HersHKovitz et al.	
	8	US-4,946,778	08-8-1990	Ladner et al.	
	9	US-5,997,863	07-7-1999	Zimmermann et al.	
	10	US-6,242,238	05-5-2001	Freeman et al.	
	11	US-5,688,679	11-18-1997	Powell	
	12	US-6,387,643	05-14-2002	Heinrikson et al.	
	13	US-6,423,312	07-23-2002	Yacoby-Zeevi	
	14	US-6,531,129	01-1-2003	Pecker et al.	
	15	US-4,455,296	06-19-1984	Hansen et al.	
	16	US-5,571,506	05-5-1996	Regan et al.	
	17	US-5,917,830	06-29-1999	Chen et al.	
	18	US-5,859,660	01-12-1999	Perkins et al.	
	19	US-5,600,366	04-4-1997	Schulman	
	20	US-6,020,931	01-1-2000	Bilbrey et al.	
	21	US-5,968,822	10-19-1999	Pecker et al.	
	22	US-6,153,187	11-28-2000	Yacoby-Zeevi	
	23	US-6,664,105	12-16-2003	Pecker et al.	
	24	US-5,145,679	08-8-1992	Hinson	
	25	US-5,736,137	07-7-1998	Anderson et al.	
	26	US-5,194,596	03-16-1993	Tischer et al.	
	27	US-5,350,836	09-27-1994	Kopchick et al.	
	28	US-6,562,950	05-13-2003	Peretz et al.	
	29	US-6,699,672	02-2-2004	Pecker et al.	
	30	US-5,580,862	03-3-1996	Rosen et al.	
	31	US-5,474,983	12-12-1995	Kuna et al.	
	32	US-2002/0102560	01-1-2002	Pecker et al.	
	33	US-6,790,658	09-14-2004	Pecker et al.	
	34	US-6,798,658	09-28-2004	Takedomi et al.	
	35	US-5,618,709	08-8-1997	Gewirtz et al.	
	36	US-5,656,595	08-12-1997	Schweighoffer et al.	
	37	US-4,683,195	07-28-1987	Mullis et al.	
	38	US-5,602,095	02-11-1997	Pastan et al.	
	39	US-4,859,581	08-22-1989	Nicholson et al.	
	40	US-4,882,318	11-21-1989	Vlodavsky et al.	
	41	US-5,129,877	07-14-1992	Gallo et al.	
	42	US-5,206,223	04-27-1993	Vlodavsky et al	
	43	US-5,332,812	07-26-1994	Nicolson et al.	


OIR
 JUL 22 2005
 JC98
 PATENT & TRADEMARK OFFICE

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Documents	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T 6
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
Examiner Signature					Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450



PTO/SB/08b (08-03)

Approved for use through 06/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-0759 INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known		
		Application Number	10/785,116	
		Filing Date	February 25, 2004	
		First Named Inventor	PECKER Iris et al	
		Group Art Unit	1652	
		Examiner Name		
Sheet		Of	Attorney Docket Number	27674
OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	44	Hulett et al. "Cloning of Mammalian Heparanase, An Important Enzyme in Tumor Invasion and Metastasis", Nature Medicine, 5(7): 803-809, 1999.		
	45	Toyoshima et al. "Human Heparanase: Purification, Characterization, Cloning, and Expression", J. of Biolog. Chemistry, 274(34): 24153-24160, 1999.		
	46	Kussie et al. "Cloning and Functional Expression of a Human Heparanase Gene", Biochemical and Biophysical Research Communication 261(1): 183-187, 1999.		
	47	Freeman et al. "Evidence that Platelet and Tumour Heparanases are Similar Enzymes", Biochem J. 342: 361-368, 1999.		
	48	Dempsey et al. "Heparanase, A Potential Regulator of CellMatrix Interactions", TIBS, 25(8): 349-351, 2000. P.350, Col.1, § 1, Col.3, § 1, Claims 1-24.		
	49	Goshen et al. "Purification and Characterization of Placental Heparanase and Its Expression by Cultured Cytotrophoblasts", Molecular Human Reproduction, 2(9): 679-684, 1996.		
	50	Freeman et al. "Human Platelet Heparanase: Purification, Characterization and Catalytic Activity", Biochem. J., 330: 1341-1350, 1998.		
	51	Vlodavsky et al. "Mammalian Heparanase: Gene Cloning, Expression and Function in Tumor Progression and Metastasis", Nature Medicine, 5(7): 793-802, XP 002139970, 1999.		
	52	Uno et al. "Antisense-Mediated Suppression of Human Heparanase Gene Expression Inhibits Pleural Dissemination of Human Cancer Cells", Cancer Research, 61(21): 7855-7860, 2001.		

Signature		Considered	
-----------	--	------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹. Applicant's unique citation designation number (optional). ². Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.